we're no. 3

Houston ranked among world's top cities of the future for global business

Houston has been recognized as a city with high potential for global business. Photo by Tim Leviston/Getty Images

When it comes to global cities on track for continued global business success, Houston comes in third on a prestigious list recently released.

The new fDi Tier 2 Cities of the Future 2020/21 evaluated second tier cities — defined as non-capital cities with a population under eight million.

Last year, Houston ranked in the No. 5 position. This year, the city moved up in the ranking and held the No. 3 spot for human capital and lifestyle and the No. 7 spot for economic growth potential.

"This ranking is further evidence of Houston's place among the world's great global cities," says Susan Davenport, chief economic development officer for the Greater Houston Partnership, in a news release. "Houston today competes at a higher level than ever before when it comes to foreign direct investment and our business ties to cities and countries around the world.

"With superior global access, a business-friendly climate, exceptional quality of life and a highly educated workforce, Houston is well positioned to continue to build on that momentum in the years ahead."

San Francisco came in at No. 1 on the list and Montreal ranked as No. 2. Austin and Dallas made the top 20 at No. 11 and No. 19, respectively. The report evaluated 116 data points across the five categories: economic potential, cost effectiveness, business friendliness, connectivity, and human capital and lifestyle.

"Houston is a remarkable city, and we are proud to be recognized as one of the world's best cities for foreign direct investment. We are the energy capital of the world, alongside the largest medical center, the Port of Houston, two world-class airports, and a growing innovation ecosystem," says Houston Mayor Sylvester Turner in the release.

"Houston is also the most diverse city in the U.S. with one in four residents born abroad. The report is also a recognition of our work with community partners over the last five years to build a more livable city. We offer world-class education, art, and culture in addition to our standing as a global business leader."

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News